Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-03-27
2007-03-27
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S155100, C424S181100, C435S069600, C435S070210, C530S387300, C530S388100, C530S388800, C530S391700
Reexamination Certificate
active
10944664
ABSTRACT:
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 6657048 (2003-12-01), Young et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: 2004/0001789 (2004-01-01), Young et al.
patent: 2004/0105815 (2004-06-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2004/0258693 (2004-12-01), Young et al.
patent: 2005/0063967 (2005-03-01), Young et al.
patent: 2003/055515 (2003-07-01), None
patent: WO2004/089989 (2004-10-01), None
Morrison et al. Proc. Natl. Acad. Sci. USA, 81:6851-6855, 1984.
Campbell et al. Biology, 5th ed. p. 856, 1999.
Co et al. Nature, 351(6):501-502, Jun. 6, 1991.
Presta et al. Biochemical Society Transactions, 30(4):487-490, 2002.
J. Berzoksky et al, “Chapter 8: Immunogenicity and antigen structure”, in Fundamental Immunology, p. 242, ed. William E. Paul, M.D., 3d ed., Raven Press, NY (1993).
J. Desousa-Hitzler et al, “Functional approach to therapeutic antibody generation yields antibodies effective against relevant tumor antigens”, Clinical Cancer Reserch, 9(16/2):6187S (Dec. 2003) Abstract.
H. Ishizuka et al, “Antitumour activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis”, Anticancer Research, 18:2513-2518 (1998).
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
Blanchard David J.
Huff Sheela J.
McHale & Slavin P.A.
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747257